Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Issue 5 (30th November 2022)

• Record Type: Journal Article
• Authors: Tabatabaee, Seyedehnarges; Rezania, Fatemeh; Alwedaie, Sayed Mohammed Jawad; Malekdar, Ensieh; Badi, Zahra; Tabatabaei, Seyed Mohammad; Mirzaasgari, Zahra
• Is Part Of: Human vaccines & immunotherapeutics. Volume 18:Issue 5(2022)
• Publication Date: 2022-11-30
• Subjects: Coronavirus 2019 -- vaccine -- Guillain-Barre syndrome -- AstraZeneca -- Sinopharm; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2022.2045153
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship.